Highlights
Predictive Value of Haptoglobin
In patients with Type 2 Diabetes (T2D), the combination of the Haptoglobin (HP) 1-1 phenotype and low baseline HP levels identifies individuals with the lowest risk for cardiovascular disease (CVD) events.
The HP 1-1 Paradox
Contrary to some prior assumptions that HP 1-1 is universally protective, higher circulating HP levels are associated with a significant increase in CVD risk, specifically within the HP 1-1 phenotype group.
Fenofibrate Interaction
The cardiovascular benefits provided by fenofibrate therapy in T2D do not appear to be modulated by HP phenotype, baseline HP levels, or the magnitude of change in HP levels during treatment.
Clinical Context and the Haptoglobin Hypothesis
Haptoglobin (HP) is a plasma protein primarily synthesized in the liver, serving a critical role as an antioxidant by binding free hemoglobin with high affinity. This binding prevents hemoglobin-induced oxidative tissue damage and facilitates its clearance via the CD163 receptor on macrophages. In humans, HP is characterized by a genetic polymorphism resulting in three main phenotypes: HP 1-1, HP 2-1, and HP 2-2.
For years, clinical research has suggested that these phenotypes carry different functional capacities. The HP 2-2 phenotype, in particular, has been associated with reduced antioxidant efficiency and impaired heme clearance, leading many to hypothesize that HP 2-2 serves as an independent risk factor for cardiovascular disease, especially in the pro-oxidative environment of Type 2 Diabetes. Furthermore, some smaller-scale studies had suggested that patients with the HP 2-2 phenotype might derive preferential benefit from antioxidant or lipid-lowering therapies, such as Vitamin E or fenofibrate. However, the interplay between HP phenotype and the actual circulating levels of the protein remained poorly understood until the analysis of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
The FIELD Sub-study: Methodology and Population
The FIELD study was a landmark randomized controlled trial investigating the effects of fenofibrate on CVD outcomes in patients with Type 2 Diabetes. This specific sub-study sought to clarify the longitudinal relationship between HP phenotype, HP levels, and new-onset CVD events over a five-year period.
The researchers determined HP phenotype and levels in 8,047 participants. Measurements were taken at baseline and again after a 16-week run-in period, which included 6 weeks of active fenofibrate therapy. The primary endpoint analyzed was total CVD events, including non-fatal myocardial infarction, stroke, cardiovascular death, and coronary/carotid revascularization. The robust sample size and the controlled nature of the FIELD trial provided a unique opportunity to evaluate whether HP could serve as a viable biomarker for risk stratification or a predictor of treatment response.
Quantitative and Qualitative Analysis: Key Findings
HP Levels and CVD Risk
Among participants in the placebo group (n = 4,030), baseline HP levels were significantly associated with the risk of total CVD events. Individuals in the highest tertile of HP levels (Tertile 3) demonstrated a 30% higher risk of CVD events compared to those in the lowest tertile (Tertile 1), with a hazard ratio (HR) of 1.30 (95% CI 1.02–1.66, P = 0.035).
The Phenotype-Level Interaction
One of the most striking findings was that the association between HP levels and CVD risk was not uniform across phenotypes. The increased risk associated with higher HP levels was primarily driven by participants with the HP 1-1 phenotype (P for interaction = 0.011). In fact, the cohort with the lowest overall CVD risk consisted of those who possessed both the HP 1-1 phenotype and HP levels in the lowest tertile. When HP levels were high, the traditionally “protective” HP 1-1 phenotype lost its advantage, showing a risk profile similar to that of HP 2-1 and HP 2-2 individuals.
Fenofibrate Outcomes
Regarding the interaction with pharmacotherapy, the sub-study found that fenofibrate’s benefit on total CVD events did not differ significantly by HP phenotype. Furthermore, neither the baseline HP levels nor the changes in HP levels induced by fenofibrate during the active run-in period served as predictors for the drug’s efficacy in reducing cardiovascular events. This suggests that while HP is a marker of risk, it is not a mediator of the specific vasculoprotective pathways targeted by fenofibrate.
Expert Commentary: Mechanistic Plausibility and Clinical Implications
The results of this FIELD sub-study challenge the simplistic view that HP phenotype alone determines cardiovascular risk in diabetes. The finding that HP 1-1 individuals with high HP levels have increased risk suggests that the quantity of the protein may reflect underlying pathological processes.
From a mechanistic perspective, elevated HP levels are often observed in states of chronic low-grade inflammation, as HP is an acute-phase reactant. In Type 2 Diabetes, where systemic inflammation and oxidative stress are prevalent, high HP levels might indicate a compensatory but insufficient response to increased hemoglobin release or a general inflammatory state that overrides the functional advantages of the HP 1-1 protein structure. Conversely, the low-risk group (HP 1-1 + low HP levels) likely represents a state of lower systemic inflammation and efficient heme clearance.
Clinically, these findings suggest that if HP is to be used for risk stratification, clinicians must consider both the genotype and the protein concentration. However, the lack of interaction with fenofibrate treatment indicates that HP status should not currently influence the decision to prescribe fibrate therapy for CVD risk reduction in T2D patients. This contrasts with some earlier, smaller trials (such as the ICARE study) that suggested a benefit of Vitamin E specifically in HP 2-2 individuals, highlighting the importance of large-scale, prospective validation in biomarker research.
Conclusion
This sub-study of the FIELD trial provides a nuanced understanding of haptoglobin’s role in the diabetic cardiovascular landscape. It demonstrates that higher baseline HP levels are a marker of increased CVD risk, particularly in those with the HP 1-1 phenotype. The identification of a specific low-risk subgroup—those with HP 1-1 and low HP levels—offers a potential avenue for more refined risk assessment. While HP status does not appear to guide fenofibrate therapy, its role as a sentinel for inflammatory and oxidative status in Type 2 Diabetes remains a compelling area for further investigation into personalized vascular medicine.
References
1. Ong KL, Januszewski AS, Francis H, et al. The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study. Eur J Prev Cardiol. 2026;33(1):132-142. doi:10.1093/eurjpc/zwaf562.
2. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849-1861.
3. Levy AP, Hochberg I, Itzkovitz N, et al. Pharmacogenomic heterogeneity in the discriminating value of haptoglobin phenotype as a predictor of clinical outcomes in the ICARE study. Eur J Cardiovasc Prev Rehabil. 2008;15(3):323-328.
